Cerebrolysin: Identity, Human Trials, and U.S. Regulatory Status

Last evidence review: August 27, 2026

Cerebrolysin is not one defined peptide. FDA’s substance record classifies it as a structurally diverse material associated with a porcine whole-brain protein fraction. Published studies describe a complex preparation rather than a single sequence with one molecular formula.

That distinction matters. A name on a vial cannot show that two preparations share the same source tissue, manufacturing process, peptide distribution, amino-acid composition, formulation, or biological activity. Human trials have studied defined Cerebrolysin preparations under specific protocols, and their findings have been mixed across populations and endpoints.

This page separates laboratory, animal, and human evidence and gives major null results equal prominence. It is not medical advice, does not provide use instructions, and does not establish that a Serum Research catalog solution is the material used in any cited study.

Identity at a glance

A UNII is a substance identifier, not an approval or quality determination. FDA’s UNII page expressly says identifier availability does not imply regulatory review or approval.[1]

Why Cerebrolysin cannot be treated like a single peptide

A chemically defined peptide can often be described by one sequence, formula, and calculated mass. Cerebrolysin is different: it is a complex biological-source preparation. Its identity depends on more than a product name or total mass. Source material, processing, composition, peptide distribution, excipients, concentration, and batch controls all affect whether two preparations are comparable.

A 2024 laboratory comparison reported substantial differences in composition and measured cell-based activity among Cerebrolysin and other peptide preparations marketed as similar.[2] That study does not prove a clinical outcome, but it demonstrates why “cerebroprotein hydrolysate,” “brain peptide,” and “Cerebrolysin” should not be treated as interchangeable labels.

What has been studied in laboratory systems?

Laboratory studies have examined composition, peptide fingerprints, cell differentiation, inflammatory markers, and neuronal-culture endpoints. In one rat-glial cell-culture experiment, selected microglial and inflammatory measures changed, while astrocyte morphology, survival, and BDNF production or release did not significantly differ.[3]

These experiments can generate mechanistic hypotheses. They cannot establish a neurological outcome in people, and they cannot authenticate an independently sourced commercial solution.

What has been studied in animals?

In a randomized blinded rat embolic-stroke study, the Cerebrolysin group differed from saline on the prespecified functional analysis, while infarct volume did not significantly differ from saline. Other tested peptide preparations did not show the same functional result.[4]

Animal models cannot establish safety or effectiveness in people. The experiment also reinforces a narrower identity point: nominally similar complex preparations may not behave alike.

What have major human trials reported?

CASTA acute ischemic-stroke trial

The double-blind placebo-controlled CASTA publication enrolled 1,070 participants. Its combined confirmatory primary endpoint did not significantly differ between groups. A post-hoc severity analysis discussed a trend in a more severe subgroup, but a post-hoc finding does not replace the null primary result.[5]

CARS rehabilitation trial

The randomized double-blind CARS study reported a greater change on its primary upper-limb motor score at day 90 in the Cerebrolysin group. The authors also noted limitations associated with a phase-2 study, including sample size, population heterogeneity, and lack of centralized review for key endpoints.[6]

Alzheimer disease comparative trial

A randomized double-blind study enrolled 217 people across Cerebrolysin, donepezil, and combination groups. The publication reported no significant group differences in cognitive, functional, or behavioral domains, while a global-outcome measure favored Cerebrolysin and the combination. The registry’s posted analysis for the ADAS-cog+ change reports no significant overall group difference.[7][8]

These results should be read together. A positive endpoint in one smaller trial does not erase a null primary endpoint in a larger trial, and neither validates a separately sourced catalog preparation.

Is Cerebrolysin still being studied?

Yes. ClinicalTrials.gov lists ongoing or planned studies, including a not-yet-recruiting randomized study after endovascular reperfusion and a small recruiting early-rehabilitation study.[9][10] Neither record has posted results as of this review.

Registration, recruitment, or a planned trial does not demonstrate a positive outcome and does not mean FDA approval is pending.

What is Cerebrolysin’s current FDA status?

FDA maintains a substance identifier for Cerebrolysin, but that is not approval. An exact-name search across the brand-name, active-ingredient-name, and generic-name fields of FDA’s official approved-application dataset returned no matching product on August 27, 2026.[1][11]

The most precise public statement is: no FDA-approved Cerebrolysin product was identified in the official approval database search. This statement does not address authorization in other countries.

Important evidence limits

• Cerebrolysin is a complex preparation, not one molecule with one sequence.
• The large CASTA trial did not meet its confirmatory primary endpoint.
• Smaller trials have reported positive findings on selected endpoints, but results vary by design and population.
• Trial findings do not establish prevention, reversal, or treatment of a neurological condition by a retail research material.
• A shared name does not demonstrate manufacturing or compositional equivalence.
• No cited source verifies the identity, concentration, purity, stability, sterility, or biological activity of a Serum Research solution.

Frequently asked questions

Is Cerebrolysin a single peptide?

No. FDA classifies it as a structurally diverse material associated with a porcine-brain protein fraction. It should not be represented with one peptide sequence or formula.

Is Cerebrolysin FDA approved in the United States?

No matching approved Cerebrolysin product was identified in the official Drugs@FDA dataset search performed for this review. An FDA UNII is an identifier, not approval.

Did the largest stroke trial meet its main endpoint?

No. The CASTA publication reported no significant difference on its combined confirmatory primary endpoint. A later subgroup analysis was post hoc.

Have any trials reported positive findings?

Yes. The smaller CARS rehabilitation trial reported a difference on its primary upper-limb motor score. That finding belongs to its specific preparation, protocol, population, and endpoint and must be read alongside trial limitations and other null findings.

Does this page show that a 60 mg catalog solution is equivalent to studied Cerebrolysin?

No. A complex preparation requires source, process, composition, formulation, concentration, and lot-level comparability evidence. Those records have not been linked to the catalog item.

Primary and official sources

1. FDA Cerebrolysin UNII record
2. Composition and cell-bioactivity comparison, PMID 38737662
3. Rat glial cell-culture study, PMID 10420388
4. Randomized blinded rat embolic-stroke comparison, PMID 30665068
5. CASTA randomized trial, PMID 22282884 and NCT00868283
6. CARS randomized trial, PMID 26564102
7. Alzheimer comparative trial publication, PMID 21679156
8. Alzheimer comparative trial posted results, NCT00911807
9. Planned post-reperfusion trial, NCT06339411
10. Recruiting rehabilitation study, NCT07043686
11. FDA Drugs@FDA search portal, Cerebrolysin search across brand, active-ingredient, and generic-name fields documented above